Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers (original) (raw)
Adams JU, Paronis CA, Holtzman SG (1990) Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J Pharmacol Exp Ther 255(3):1027–1032 PubMedCAS Google Scholar
Barrett AC, Smith ES, Picker MJ (2003) Use of irreversible antagonists to determine the relative efficacy of mu opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox. J Pharmacol Exp Ther 1061–1070
Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988a) A clinical trial with buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72–78 ArticlePubMedCAS Google Scholar
Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988b) Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247:47 53 PubMedCAS Google Scholar
Bickel WK, Amass L, Crean JP, Badger GJ (1999) Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology 146:111–118 ArticlePubMedCAS Google Scholar
Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B 220:141–162 ArticlePubMedCAS Google Scholar
Black JW, Leff P, Shankley NP, Wood J (1985) An operational model of pharmacological agonism: the effects of E/[_A_] curve shape on agonist dissociation constant estimation. Br J Pharmacol 84:561–571 PubMedCAS Google Scholar
Chiang CN, Hawks RL (2003) Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 70:S39–S47 ArticlePubMedCAS Google Scholar
Comer SD, Burke TF, Lewis JW, Woods JH (1992) Clocinnamox: a novel, systemically-active, irreversible opioid antagonist. J Pharmacol Exp Ther 262:1051–1056 PubMedCAS Google Scholar
Comer SD, Collins ED, Fischman MW (1997) Choice between money and intranasal heroin in morphine-maintained humans. Behav Pharmacol 8:667–690 Article Google Scholar
Comer SD, Collins ED, MacArthur RB, Fischman MW (1999) Comparison of intranasal and intravenous heroin self-administration by morphine-maintained humans. Psychopharmacology 143:327–338 ArticlePubMedCAS Google Scholar
Comer SD, Collins ED, Fischman MW (2001) Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology 154:28–37 ArticlePubMedCAS Google Scholar
Evans SM, Foltin RW, Levin FR, Fischman MW (1995) Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 6:176–186 ArticlePubMedCAS Google Scholar
Foltin RW, Fischman MW (1992) The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. J Pharmacol Exp Ther 261(2):623–632 PubMedCAS Google Scholar
Fraser HF,van Horn GD, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs. (B) A short-term ldquo;direct” addiction test. J Pharmacol Exp Ther 133:371–387 PubMedCAS Google Scholar
Furchgott RF (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor–agonist complexes. Adv Drug Res 3:21–56 Google Scholar
Greenwald MK, Schuh KJ, Hopper JA, Schuster CR, Johanson C-E (2002) Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 160:344–352 ArticlePubMedCAS Google Scholar
Greenwald MK, Johanson C-E, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta J-K (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000–2009 PubMedCAS Google Scholar
Hambrook J, Rance M (1976) The interaction of buprenorphine with the opiate receptor: lipophylicity as a determining factor in drug-receptor kinetics. In: Kosterlitz H (ed) Opiates and endogenous peptides. North-Holland, Amsterdam, pp 295–301 Google Scholar
Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13:293–308 ArticlePubMedCAS Google Scholar
Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT (2004) Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 43(5):329–40 ArticlePubMedCAS Google Scholar
Johnson RE, Jaffe JH, Fudala PJ (1992) A controlled trial of buprenorphine treatment for opioid dependence. J Am Med Assoc 267(20):2750–2755 ArticleCAS Google Scholar
Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New Engl J Med 343(18):1290–1297 ArticlePubMedCAS Google Scholar
Johnson RE, Strain EC, Amass L (2003) Buprenorphine: how to use it right. Drug Alcohol Depend 70:S59–S77 ArticlePubMedCAS Google Scholar
Kelly TH, Foltin RW, Emurian CS, Fischman MW (1993) Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. J Anal Toxicol 17:264–272 PubMedCAS Google Scholar
Ling W, Wesson DR, Charuvastra C, Klett CJ (1996) A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53:401–407 PubMedCAS Google Scholar
Martin TJ, Dworkin SI, Smith JE (1995) Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats. J Pharmacol Ther Exp 272:1135–1140 CAS Google Scholar
Martin TJ, DeMontis MG, Kim SA, Sizemore GM, Dworkin SI, Smith JE (1998) Effects of beta-funaltrexamine on dose–effect curves for heroin self-administration in rats: comparison with alteration of [3H]DAMGO binding to rat brain sections. Drug Alcohol Depend 52:135–147 ArticlePubMedCAS Google Scholar
McLeod DR, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the Digit Symbol Substitution Test (DSST). Behav Res Meth Instrum 14:463–466 Google Scholar
Mello NK, Mendelson JH (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207:657–659 ArticlePubMedCAS Google Scholar
Mello NK, Mendelson JH, Kuehnle JC (1982) Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther 223:30–39 PubMedCAS Google Scholar
Mello NK, Bree MP, Mendelson JH (1983) Comparison of buprenorphine and methadone effects on opiate self-administration in primates. J Pharmacol Exp Ther 225:378–386 PubMedCAS Google Scholar
Miller TP, Taylor JL, Tinklenberg JR (1988) A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics. Neuropsychobiology 19:90–96 PubMedCAS Google Scholar
Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, Mendelson JE (1999) Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 39:619–623 ArticlePubMedCAS Google Scholar
Negus SS, Brandt MR, Gatch MB, Mello NK (2003) Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine. Drug Alcohol Depend 70(1):17–27 ArticlePubMedCAS Google Scholar
Pitts RC, Allen RA, Walker EA, Dykstra LA (1998) Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys. J Pharmacol Exp Ther 285:1197–1206 PubMedCAS Google Scholar
Raffa RB, Porreca F, Cowan A, Tallarida RJ (1982) Morphine–receptor dissociation constant and the stimulus effect relation for inhibition of gastrointestinal transit in the rat. Eur J Pharmacol 79:11–16 ArticlePubMedCAS Google Scholar
Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151:1025–1030 PubMedCAS Google Scholar
Tallarida RJ, Cowan A (1982) The affinity of morphine for its pharmacologic receptor in vivo. J Pharmacol Exp Ther 222:198–201 PubMedCAS Google Scholar
Walker EA, Zernig G, Woods JH (1995) Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273:1345–1352 PubMedCAS Google Scholar
Walker EA, Zernig G, Young AM (1998) In vivo apparent affinity and efficacy estimates for μ opiates in a rat tail-withdrawal assay. Psychopharmacology 136:15–23 ArticlePubMedCAS Google Scholar
Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569–580 ArticlePubMedCAS Google Scholar
Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274:361–372 PubMedCAS Google Scholar
Ward SJ, Portoghese PS, Takemori AE (1982) Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther 220(3):494–498 PubMedCAS Google Scholar
Wesnes K, Warburton DM (1983) Effects of smoking on rapid information processing performance. Neuropsychobiology 9:223–229 PubMedCAS Google Scholar
Winger G, Woods JH (1996) Effects of buprenorphine on behaviour maintained by heroin and alfentanil in rhesus monkeys. Behav Pharmacol 7(2):155–159 ArticlePubMedCAS Google Scholar
Wolfram S (2003) The Mathematica book, 2nd edn. Wolfram Media/Cambridge University Press, Champaign, IL Google Scholar
Zacny JP, Conley K, Galinkin J (1997) Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 282:1187–1197 PubMedCAS Google Scholar
Zacny JP, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C (2003) College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 69:215–232 ArticlePubMed Google Scholar
Zernig G, Issaevitch T (1995) Software for the calculation of agonist efficacy and apparent in vivo affinity by simultaneous analysis of several dose–response curves. Wolfram Research, Champaign, IL Google Scholar
Zernig G, Butelman ER, Lewis JW, Walker EA, Woods JH (1994) In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 269:57–65 PubMedCAS Google Scholar
Zernig G, Issaevitch T, Woods JH (1996) Calculation of agonist efficacy, apparent affinity, and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches. J Pharmacol Toxicol Methods 35:223–237 ArticlePubMedCAS Google Scholar